Daniel L Edmonston (Daniel Edmonston)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Cardiovascular Risk Factors

Direct Oral Anticoagulants

Iron Deficiency

Venous Thromboembolism

Top Venues

Nature reviews. Nephrology

Nature reviews. Cardiology

Journal of the American Heart Association

Journal of hospital medicine

Duke Clinical Research Institute

Mercer University School of Medicine (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Duke Clinical Research Institute Jul 01 2019

United States

Clinical Investigator :: Medicine

Duke University School of Medicine Jul 01 2019

United States

Nephrologist :: Medicine

Education History

Mercer University School of Medicine Aug 01 2009 - May 03 2013

United States

PHD

Publications

Daniel L Edmonston, Tamara Isakova, Myles Wolf, null null
Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease. Journal of the American Heart Association (2023)
Daniel L Edmonston, Alexander Grabner, Myles Wolf
FGF23 and klotho at the intersection of kidney and cardiovascular disease. Nature reviews. Cardiology (2023)
Suchita Shah Sata, Susan E Spratt, Daniel L Edmonston, Neha J Pagidipati
Clinical progress note: Indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients. Journal of hospital medicine 17 (5) (2022)
Andrew M South, Laurie Tomlinson, Daniel L Edmonston, Swapnil Hiremath, Matthew A Sparks
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nature reviews. Nephrology 16 (6) (2020)
Daniel L Edmonston, Myles Wolf
FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nature reviews. Nephrology 16 (1) (2019)